Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution

Daniel Lee, Anand V Mantravadi, Jonathan S Myers Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, USA Abstract: Glaucoma is a leading cause of irreversible blindness worldwide. The reduction of intraocular pressure has been well established as an effective treatment to prevent both the deve...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lee D, Mantravadi AV, Myers JS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	bimatoprost ocular hypertension glaucoma Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8265e3752b834f64bb272eff85758b90
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8265e3752b834f64bb272eff85758b90
record_format	dspace
spelling	oai:doaj.org-article:8265e3752b834f64bb272eff85758b902021-12-02T05:04:02ZPatient considerations in ocular hypertension: role of bimatoprost ophthalmic solution1177-5483https://doaj.org/article/8265e3752b834f64bb272eff85758b902017-07-01T00:00:00Zhttps://www.dovepress.com/patient-considerations-in-ocular-hypertension-role-of-bimatoprost-opht-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Daniel Lee, Anand V Mantravadi, Jonathan S Myers Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, USA Abstract: Glaucoma is a leading cause of irreversible blindness worldwide. The reduction of intraocular pressure has been well established as an effective treatment to prevent both the development and the progression of all forms of glaucoma. Bimatoprost 0.03% ophthalmic solution, introduced in 2001, is a synthetic prostamide with the unique mechanism of improving both uveoscleral and trabecular outflow. Comparative studies with other pharmacotherapies have shown favorable results for bimatoprost as a potent ocular hypotensive agent that is generally well tolerated. Common side effects include conjunctival hyperemia, eyelash growth, iris pigmentation and periorbital changes. Hyperemia rates were reduced following the introduction of bimatoprost 0.01%. Bimatoprost should be used with caution in those with higher risk of developing ocular inflammation and macular edema. However, the perceived risk of bimatoprost in these patient populations is likely greater than the actual risk observed in practice. Bimatoprost is currently in the center of several clinical trials including its use for dermatologic applications and sustained-release therapies for the treatment of ocular hypertension and glaucoma. Keywords: bimatoprost, ocular hypertension, glaucomaLee DMantravadi AVMyers JSDove Medical Pressarticlebimatoprostocular hypertensionglaucomaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 1273-1280 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	bimatoprost ocular hypertension glaucoma Ophthalmology RE1-994
spellingShingle	bimatoprost ocular hypertension glaucoma Ophthalmology RE1-994 Lee D Mantravadi AV Myers JS Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
description	Daniel Lee, Anand V Mantravadi, Jonathan S Myers Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, USA Abstract: Glaucoma is a leading cause of irreversible blindness worldwide. The reduction of intraocular pressure has been well established as an effective treatment to prevent both the development and the progression of all forms of glaucoma. Bimatoprost 0.03% ophthalmic solution, introduced in 2001, is a synthetic prostamide with the unique mechanism of improving both uveoscleral and trabecular outflow. Comparative studies with other pharmacotherapies have shown favorable results for bimatoprost as a potent ocular hypotensive agent that is generally well tolerated. Common side effects include conjunctival hyperemia, eyelash growth, iris pigmentation and periorbital changes. Hyperemia rates were reduced following the introduction of bimatoprost 0.01%. Bimatoprost should be used with caution in those with higher risk of developing ocular inflammation and macular edema. However, the perceived risk of bimatoprost in these patient populations is likely greater than the actual risk observed in practice. Bimatoprost is currently in the center of several clinical trials including its use for dermatologic applications and sustained-release therapies for the treatment of ocular hypertension and glaucoma. Keywords: bimatoprost, ocular hypertension, glaucoma
format	article
author	Lee D Mantravadi AV Myers JS
author_facet	Lee D Mantravadi AV Myers JS
author_sort	Lee D
title	Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
title_short	Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
title_full	Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
title_fullStr	Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
title_full_unstemmed	Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
title_sort	patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/8265e3752b834f64bb272eff85758b90
work_keys_str_mv	AT leed patientconsiderationsinocularhypertensionroleofbimatoprostophthalmicsolution AT mantravadiav patientconsiderationsinocularhypertensionroleofbimatoprostophthalmicsolution AT myersjs patientconsiderationsinocularhypertensionroleofbimatoprostophthalmicsolution
_version_	1718400661412904960

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution

Ejemplares similares